WINT vs. ACXP, SLXN, HCWB, CHRO, PRTG, OBSV, GTBP, CVM, APLM, and SBFM
Should you be buying Windtree Therapeutics stock or one of its competitors? The main competitors of Windtree Therapeutics include Acurx Pharmaceuticals (ACXP), Silexion Therapeutics (SLXN), HCW Biologics (HCWB), Chromocell Therapeutics (CHRO), Portage Biotech (PRTG), ObsEva (OBSV), GT Biopharma (GTBP), CEL-SCI (CVM), Apollomics (APLM), and Sunshine Biopharma (SBFM). These companies are all part of the "pharmaceutical products" industry.
Windtree Therapeutics vs. Its Competitors
Windtree Therapeutics (NASDAQ:WINT) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.
Acurx Pharmaceuticals received 14 more outperform votes than Windtree Therapeutics when rated by MarketBeat users. Likewise, 94.44% of users gave Acurx Pharmaceuticals an outperform vote while only 37.50% of users gave Windtree Therapeutics an outperform vote.
In the previous week, Windtree Therapeutics and Windtree Therapeutics both had 6 articles in the media. Acurx Pharmaceuticals' average media sentiment score of 1.87 beat Windtree Therapeutics' score of 0.62 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.
Windtree Therapeutics has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.38, indicating that its stock price is 238% less volatile than the S&P 500.
Windtree Therapeutics presently has a consensus price target of $350.00, suggesting a potential upside of 58,526.47%. Acurx Pharmaceuticals has a consensus price target of $8.00, suggesting a potential upside of 874.78%. Given Windtree Therapeutics' higher probable upside, analysts plainly believe Windtree Therapeutics is more favorable than Acurx Pharmaceuticals.
Windtree Therapeutics' return on equity of -227.93% beat Acurx Pharmaceuticals' return on equity.
Acurx Pharmaceuticals is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.
29.3% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are owned by institutional investors. 0.3% of Windtree Therapeutics shares are owned by insiders. Comparatively, 26.0% of Acurx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Windtree Therapeutics and Acurx Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.
Get Windtree Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding WINT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Windtree Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:WINT) was last updated on 6/18/2025 by MarketBeat.com Staff
Buy WINT Stock Free WINT Stock Alerts